Cover Image
市場調查報告書

雷諾氏症:開發平台分析

Raynauds Disease - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 200484
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
雷諾氏症:開發平台分析 Raynauds Disease - Pipeline Review, H1 2017
出版日期: 2017年03月15日 內容資訊: 英文 49 Pages
簡介

所謂雷諾氏現象(RP),是指氣溫大幅上升、下降和遇到情緒壓力時,手指和腳尖變色的現象。皮膚的變色,是由於血管的異常收縮使末梢組織的血液供應量減少而產生。由於長時間的供氧不足導致手指變藍。如果血管再次擴張,便在該處產生「潮紅」現象,手指變紅。這樣的皮膚連續變色是雷諾氏症的特徵。雷諾氏症的治療包含了可保持血管擴張狀態的醫藥品等。用溫水浸手,及寒冷的時候保持手腳溫暖狀態等,往往相當有效。

本報告提供全球各國治療雷諾氏症所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查結果。

簡介

  • 分析範圍

治療藥的開發

  • 雷諾氏症開發中產品:概要
  • 雷諾氏症開發中產品:比較分析

雷諾氏症概要

治療藥的開發

  • 雷諾氏症開發中產品:概要
  • 雷諾氏症開發中產品:比較分析

各企業開發中的雷諾氏症治療藥

大學/研究機關研究中的雷諾氏症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

雷諾氏症治療藥:開發中的產品一覽(各企業)

雷諾氏症治療藥:研究中的產品一覽(大學/研究機關別)

雷諾氏症開發治療藥的企業

  • Allergan Plc
  • Apricus Biosciences, Inc.
  • Bayer AG
  • Covis Pharmaceuticals, Inc.
  • Human Stem Cells Institute

雷諾氏症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • acetylcysteine
  • alprostadil
  • ELS-140
  • Neovasculgen
  • nitroglycerin
  • onabotulinumtoxin A
  • riociguat

雷諾氏症治療藥:最新開發平台趨勢

雷諾氏症治療藥:暫停中的計劃

雷諾氏症治療藥:開發中止的產品

雷諾氏症相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9054IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Raynauds Disease - Pipeline Review, H1 2017, provides an overview of the Raynauds Disease (Cardiovascular) pipeline landscape.

Raynauds disease is a common condition that affects the blood supply to certain parts of the body, usually the fingers and toes. Predisposing factors include age, gender, family history and smoking. Symptoms include fingers, toes, ears, or nose to become white, and then turn blue. Treatment includes vasodilator, alpha blockers and calcium channel blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Raynauds Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Raynauds Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Raynauds Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively. Similarly, the Universities portfolio in Unknown stages comprises 1 molecules, respectively.

Raynauds Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Raynauds Disease (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Raynauds Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Raynauds Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Raynauds Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Raynauds Disease (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Raynauds Disease (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Raynauds Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Raynauds Disease - Overview
  • Raynauds Disease - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Raynauds Disease - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Raynauds Disease - Companies Involved in Therapeutics Development
  • Allergan Plc
  • Apricus Biosciences Inc
  • Covis Pharmaceuticals Inc
  • Human Stem Cells Institute
  • Raynauds Disease - Drug Profiles
  • alprostadil - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug to Block TRPM8 for Raynauds Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ELS-140 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Neovasculgen - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nitroglycerin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • onabotulinumtoxinA - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Raynauds Disease - Dormant Projects
  • Raynauds Disease - Discontinued Products
  • Raynauds Disease - Product Development Milestones
  • Featured News & Press Releases
  • Mar 08, 2016: Apricus Biosciences to Present at the 28th Annual ROTH Conference
  • Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference, Provide Update on Vitaros
  • Aug 05, 2015: Apricus Biosciences to Provide Update On The European Launch of Vitaros at the Canaccord Genuity 35th Annual Growth Conference
  • Apr 28, 2015: Apricus Biosciences to Present at Two Investor Conferences in May
  • Jan 27, 2015: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa
  • Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud's Phenomenon
  • Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa
  • Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum
  • May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud's Phenomenon
  • Dec 13, 2012: MediQuest Therapeutics To Conduct Meetings At J.P. Morgan Conference Regarding Phase III Topical Formulation Vascana
  • May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud's Phenomenon
  • Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa
  • Sep 22, 2010: FDA Guides Apricus Bio On RayVa's Approvability For Raynaud's Syndrome Secondary To Scleroderma
  • Jan 10, 2006: MediQuest Therapeutics Receives Special Protocol Assessment From The U.S. FDA
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Raynauds Disease, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Raynauds Disease - Pipeline by Allergan Plc, H1 2017
  • Raynauds Disease - Pipeline by Apricus Biosciences Inc, H1 2017
  • Raynauds Disease - Pipeline by Covis Pharmaceuticals Inc, H1 2017
  • Raynauds Disease - Pipeline by Human Stem Cells Institute, H1 2017
  • Raynauds Disease - Dormant Projects, H1 2017
  • Raynauds Disease - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Raynauds Disease, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top